BB's Stock Haven

[sweet crude]

TEDG --> $1.31 target (bird flu)

VACCINE PRODUCTION

China BioPharma's recently completed production facility is the largest and best human-vaccine production facility in China, and is also the nation's main vaccine production base whenever there is an epidemic disease outbreak within the region. Basicly, if there is an outbreak of general Influenza or the deadly Avian H5N1 Influenza (bird flu) virus, China BioPharma's vaccine production facility will be a key player in producing and distributing vaccines out to the Chinese government. The facility currently has around 140 employees. (see photo)


AVIAN H5N1 RESEARCH

China BioPharma's main focus is on vaccines for highly virulant and contagious diseases such as Ebola, SARS, and Influenza. To that effect, TEDG will be a major player in creating and mass producing a vaccine for any potential Avian Bird Flu outbreak if the need should arise in China. The company specializes in vaccines for highly contagious diseases.


PRICE TARGET OF $1.31

TEDG reported around $9 million in sales for fiscal year 2005, along with $1.5 million in net income profit. Based on other biotech 'bird flu' plays within the sector, and only 82 million shares issued and outstanding we feel TEDG should have a fair market cap value of at least $108 million. This valuation would still only give TEDG a price/sales ratio of 12 as compared to others in the sector ranging from 12 to 653 times sales.

$9 million (revenue) x 12 (price to sales) = $108 million market cap

($108 million market cap / 82 million shares outstanding = $1.31 a share)

http://www.theasianinvestor.com/reports/tedg.htm